ArticlePeerJ2026
IL20RB promotes proliferation and migration in clear cell renal cell carcinoma and is associated with immune infiltration.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IL20RB, interleukin 20 receptor subunit beta, functions as a cytokine receptor subunit coding gene and has been discovered to serve an essential function in human malignancies. However, the link between IL20RB expression, clinical outcomes, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC) remains unclear. Methods: The Cancer Genome Atlas (TCGA) was utilized to compile data on the IL20RB expression in both normal and ccRCC tissues. The link between IL20RB expression and clinicopathologic characteristics was examined utilizing the TCGA database. Kaplan-Meier survival curves were employed for performing the survival analysis. Furthermore, a protein network involving IL20RB was established using data from the GeneMANIA database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were undertaken, and the relationship between IL20RB and tumor immune infiltration was examined via single-sample GSEA (ssGSEA). Additional examination of the link between tumor-infiltrating immune cells (TIIC) and IL20RB was executed utilizing the Tumor Immune Estimation Resource (TIMER) and TISIDB databases. IL20RB expression in tumor specimens was detected through immunohistochemistry (IHC). IL20RB expression levels in tumor cells were confirmed via Western blot analysis. Cell counting kit-8 (CCK-8) and colony formation assays evaluated IL20RB's impact on ccRCC cell viability. Wound Healing and Transwell assays assessed IL20RB's influence on ccRCC cell migration. Results: Peritumor samples exhibited notably reduced IL20RB expression compared to ccRCC samples. IL20RB expression levels correlated markedly with sample classification, lymph node status, tumor differentiation, and disease progression. Enhanced IL20RB expression is linked to poor Disease-Specific Survival (DSS) and Overall Survival (OS) in ccRCC patients ( Conclusion: Heightened IL20RB expression is linked to a dismal prognosis and infiltration of immune cells in ccRCC, indicating its potential importance in the development of immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.